


Products

Peakdale has a global reputation for designing, producing and supplying novel compound intermediates. We have hundreds of proven building blocks and thousands of new compounds available from stock in milligram to kilogram quantities. Brief descriptions further details are available through the links above.

Screening Compounds

Novel compounds used for initial screening for biological activity are available through our screening compound service. We have designed and synthesised many 10s of thousands of compounds for our customers. We currently have over 7000 non-exclusive screening compounds available from stock.



Our parallel synthesis labs support the further development of our collection and our site is available for exclusive contracts in the areas of hit discovery, hit-to-lead and lead optimisation. We have access to high throughput pharmacokinetic testing and can simultaneously look at safety/tox profile of a lead series during the lead optimisation phase. Further information under the Discovery Services heading.

We are currently collaborating with De Novo Pharmaceuticals, a leading *in silico* D company, to synthesise a new range of lead-like molecules designed specifically against the G-Protein Coupled Receptor class of biological targets. These will become available from

Intermediates Catalogue



Novel building blocks are key to the success of many drug discoveries. Peakdale has designed around 500 non-exclusive intermediates available from stock and some of these have become components of emerging drug candidates.

We aim to add approx 200 new compounds each year and publish each January. Through a recent collaboration with exchem.org, we have introduced a range of bis(methylsulfonyl)aryl compounds. More available by [clicking here](#).

[CONTACT US](#) | [SITE MAP](#)

25

Peakdale Molecular Limited

History

- 1992 Peakdale Founded in Glossop, UK

Peakdale was founded by Ray Fisher in 1992. Ray obtained his PhD in organic chemistry has since enjoyed over 25 years of research in synthetic organic chemistry, carrying out synthetic and developing biologically active molecules for screening. In that time he has over 10,000 new chemicals and is named as the inventor on a number of patents.

- 1996 Peakdale reaches 12 staff

Peakdale grew steadily through the 1990s, gaining a reputation with a number of major pharmaceutical companies for providing quality custom synthesis, coupled with timely delivery and reliability. Many of the Company's compounds were small building blocks and the huge demand for their creation of the Intermediates catalogue. Advances in the area of High Throughput Screening led to a demand for small quantities of drug-like molecules for biological testing. Peakdale has 7000 novel screening compounds designed around novel chemotypes and is now applying this chemistry to target further libraries of compounds against specific biological targets.

- 2000 Peakdale finds new site

By the late 1990s, Peakdale had outgrown its 2000 sq.ft. facility in Glossop and the hunt for a new site to allow the company to expand. The land was identified in late 2000 and built in 2001.

- 2002 Peakdale moves to Chapel-en-le-Frith – staff reaches 40

In 2002, Peakdale completed its move into a brand new, state-of-the-art 40,000 sq.ft. facility in Chapel-en-le-Frith, UK, designed to house 100 scientists. In the first expansion phase, Peakdale increased staff from 12 to 40 – an increase from 6 to 30 chemists, occupying five standard laboratory units. Peakdale also set up its own, in-house analytical department.


- 2003 Peakdale expands again – staff reaches 60

Following a very successful increase in business throughout 2002, Peakdale fitted out a further two laboratory units. One has become Peakdale's own in-house kilo-scale lab and the other is dedicated to the needs of parallel synthesis with the accompanying capital equipment investment.

From small beginnings, Peakdale is now the fastest growing contract chemistry company and works to maintain its world-class reputation as an innovative chemistry provider.

CONTACT US | SITE MAP

PF



Better Drug Molecules. Discovered Faster

Peakdale is the fastest growing contract chemistry company in the UK. Our business is dedicated to supporting the research and development activities of pharmaceutical and biotechnology companies worldwide.

Our mission is to improve the efficiency and effectiveness of drug discovery and development by providing a range of services that deliver cost-effective results against demanding time scales.

We offer:

- Novel chemicals through our Intermediates Catalogue
- Lead-like molecules through our Screening Compounds
- Chemistry on demand through our Custom Synthesis Service
- Drug Discovery expertise through our Contract Research Service

Please browse our website to learn more about us.

[CONTACT US](#) | [SITE MAP](#)

Latest News

01/03/2004
Glaxosmithkline And Peakdale
Extend RI CEDD Agreement &

19/01/2004
New Intermediates Catalogue
Informex 2004 [click here](#)



Log-in below to access our

Username:

Password:

If you have NOT previously
this site please [click here](#) to re



ACCELERATING DRUG DISCOVERY THROUGH SUPERIOR

SCIENCE & TECHNOLOGY | TRIPOS PROFILE | INVESTOR RELATIONS | CUSTOMER RESOURCES

PRINT

INFORMATION-DRIVEN CHEMISTRY

Research Collaborations

LeadFocus

LeadHopping

Informatics

Collaborators

Chemical Compound Libraries

Targeted Compound Sets

LeadQuest Compounds

LeadQuest Online

LeadScreen Compound Screening Sets

Process

Technologies

Advanced Data Mining

Lab

Chemical Process

DISCOVERY INFORMATICS PRODUCTS

DISCOVERY INFORMATICS SERVICES

BIBLIOGRAPHY

CONTACT US
SEARCH

Chemical Compound Libraries

LeadQuest-Designed to be Drug-like

Tripos emphasizes "design" in its LeadQuest® compound libraries because that is what sets our screening libraries apart from others. Customers who screen LeadQuest the maximum amount of information from each set systematically explore relevant variable space, and ensure that each compound contributes new information.

Tripos' LeadQuest libraries are designed, synthesized, analyzed using an information-driven manufacturing process. ChemSpace® integrates chemistry and informatics to ensure all compounds are drug-like, are relevant to medicinal chemistry, and have proven synthetic accessibility.

Tripos LeadQuest compound libraries are distinguished by their:

- Novelty and Diversity - compounds not found in competitor's databases
- Relevance to drug discovery - Designed to be drug-like, synthetically accessible, with literature proof for bioactivity
- Proven Technology - Increased leads found by customers and in a recent refereed publication
- High Purity
- Rapid Follow-Up - Experimentally validated compounds make possible
 - Rapid resupply from internal stocks
 - Rapid resynthesis of quantities from 100-10g
 - Custom lead optimization services via LeadQuest (new structures similar to a given lead) or LeadHopping™ (structurally distinct compounds with similar shape to initial lead)
- Informatics-Driven Process - based on ChemSpace (proprietary, rapid library design technology), ChemCore (global, dynamic chemical tracking) that integrates all aspects of research and production

and Tripos' vast, growing virtual libraries.

- **Experienced Drug Discovery Staff – decades of life-science experience, including pharmaceuticals and biotechnology**

These libraries are designed to elucidate families of hits across multiple target areas. Specifically,

- **LeadQuest-** The complete, currently available over 80,000 drug-relevant, synthetically feasible general screening compounds available for individual selection (cherry picking). Structures and analogs available online.
- **LeadScreen™** - a 50K pre-selected subset of the library, pre-formatted and ready to screen.
- Custom libraries available through LeadFocus LeadHopping services



MAYBRIDGE

Bringing life to
drug discovery

- **Search and Order**
Click here to
download or access
our latest compound
databases

- Our Company
- Maybridge
Building Blocks
- Custom Libraries
- Screening Collection
- Chemistry Services
for Drug Discovery
- Our People
- Careers with us
- Forthcoming events
- Literature Downloads
- Useful Links
- Press Room
- Contact Us

Maybridge... Bringing Life to Drug

At Maybridge, our aim is simple - to shorten the drug discovery process by providing products and services for drug discovery research and chemistry:

- heterocyclic Building Blocks and Reactive Intermediates suitable for medicinal chemistry, and specifically designed for hit-to-lead and target validation programmes. These building blocks, and the expertise gained in their synthesis, underpin the products and services that Maybridge can offer.

- a new Custom Libraries service which utilises Maybridge's expertise in medicinal chemistry and captures the diversity of the Maybridge Building Blocks.

- a reputable, high-quality and diverse hit-like Screening Collection for target validation programmes.

- Chemistry Services for Drug Discovery, where customers can access our Screening collection, by accessing the heterocyclic and medicinal chemistry expertise at Maybridge, to progress discovery research programmes.



See it. Want it.
Get it. Done.

The new Maybridge Group
Discover. Chemistry. Catalogue.





MAYBRIDGE

- ☐ **Search and Order:**
Click here to
download or access
our latest compound
databases
- ☐ Our Company
- ☐ Maybridge
Building Blocks
- ☐ Custom Libraries
- ☒ Chemistry Services
for Drug Discovery
- ☐ Our People
- ☐ Careers with us
- ☐ Forthcoming events
- ☐ Literature Downloads
- ☐ Useful Links
- ☐ Press Room
- ☐ Contact Us

Maybridge Screening Collection

The drug discovery process is long and expensive..... our aim is to shorten this process by producing high-quality, hit-like, lead-like and drug-like compounds, which generate quality valuable data from screening programmes.

The Maybridge Screening collection consists of over 55,000 organic compounds, largely produced by us at Maybridge. These are individually designed compounds, produced by innovative synthetic techniques, based on over 40 years of experience in heterocyclic chemistry.

The compounds in our collection are

• Diverse

An independent study carried out by McGregor and Pallai comparing the diversity of 10 commercially available libraries and the Available Chemicals Directory (ACD) showed that out of the libraries that were produced in-house, Maybridge had the most diverse library i.e. the most singletons (clusters with one member), and the highest number of clusters. (Ref. The Journal of Chemical Information and Computer Sciences 1997,37,443-448)

• Drug-like, and generally follow Lipinski's rule of 5

"Of the ~400,000 pharmacophores* in the world drug index ~87% are expressed by the Maybridge Screening collection." (*Calculations carried out by Oxford Molecular using Chem-X definition, i.e. triplets of H-bond acceptors, H-bond donors, aromatic ring centres and positive nitrogen atoms.)

The compounds in the Maybridge collection generally obey Lipinski's** "rule of five" and so demonstrate good ADME (absorption, distribution, metabolism and excretion) profiles, which makes them ideal candidates for development beyond the initial Screening assay.

Lipinski	Maybridge Screening Collection
< 5 H-bond donors	99.7% <5
<10 H-bond acceptors	99.8% <10

cLog P <5	mean log P 3.23, 94% in range -0.11 to 6.3
Mol. Weight <500	mean mol. weight 325, 95% in range 150-500

See the evidence [here!](#)

All the data contained within the graphs was calculated at Maybridge.

** Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1996). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews* 23 3-25.

• High-quality

- Analysis of new Screening compounds is by appropriate methodology, selected from:
 - Nuclear Magnetic Resonance Spectroscopy (NMR)
 - Infra-Red Spectroscopy (FT-IR)
 - Liquid Chromatography-Mass Spectrometry (LC-MS)
 - High Performance Liquid Chromatography (HPLC)
 - Elemental Analysis
- The purity of the large majority of new Screening compounds is typically over 95%, although minimum purity in the Screening Collection databases for all compounds is stated as 90%.
- Reactive molecules are excluded in order to reduce the number of false positives. ([click here for full details](#))

• Available in high stock quantities

We aim to produce thousands of compounds a year and many of them are available in high stock quantities. Typically, about 98% of the compounds in our collection are available in >5mg stock quantities and over 90% of the compounds are available in >50mg stock quantities. Indeed a large proportion of our collection is available in gram quantities and new compounds are typically produced at 200mg+ levels. This means we can ensure a very high level of resupply of originally tested compounds.

• Solids, for ease of plating

Our compounds can be supplied on plates or in vials, in micromolar or mg quantities and, if required, in frozen solutions.

The Maybridge Screening Collection database now includes **calculated key physical and ADME data:**

- Intestinal absorption
- Blood Brain Barrier distribution

- Aqueous solubility
- clogP
- H-bond acceptors
- H-bond donors
- Rotatable bonds

The database, in various formats, is available to download from this website, or email information@maybridge.com with your request.

Please refer to our literature download page to download and request information about our Screening Collection.

 [Top](#)

 [Back](#)

FAQ

ON-LINE
ORDERING

ASINEX

HOME

MAP

CONTACTS

Intelligent Chemistry for Lead Discovery & Lead Optimization

About ASINEX News Products Services Online feedback



Mailing address

ASINEX Ltd.

5 Gabrachevskogo St. Bldg 8,
Moscow 123667, Russia

Phone +7 095 780 3411

+7 095 728 3891

Fax +7 095 780 3419

E-mail asinex@asinex.com

Web site

<http://www.asinex.com>

Welcome

ASINEX, the leading European provider of Lead Generation and Optimisation Services.

We have been providing our customers with diverse small molecule compounds for 9 years. ASINEX's libraries have proved to be a rich source of 'hit' compounds.

Many of our customers choose to come back to us with the 'hits' that they have found in our collections in order to make use of our efficient and cost-effective optimization service.

To learn more about ASINEX's outsourcing solutions, please visit services and press release sections of our website.

➤ [More about ASINEX](#)

LeadGen Libraries

Several focused, pre-formatted libraries. The more cost effective way to generate leads.

Products news

ASINEX has recently launched 4 advanced Targeted Libraries.

Latest press releases

- March, 2004. ➤ [ASINEX and SIENABIOTEC announce Lead Generation Collaboration](#)
- February, 2004. ➤ [ASINEX and Proteom Announce Successful BioScreening Project](#)
- January, 2004. ➤ [ASINEX announces 1 year extension to Lead Optimization program with Avalon Pharmaceuticals](#)
- October, 2003. ➤ [ASINEX announces successful Lead Optimization project with Asahi Kasei](#)
- July, 2003. ➤ [ASINEX Announces One Year Extension to Collaboration with Johnson and Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. \(J&JPRD\)](#)
- April, 2003. ➤ [ASINEX Announces Multi-ETC deal with Bioyitum](#)

➤ [More press releases](#)

Online Ordering

ASINEX is pleased to announce the opportunity to purchase compounds from us on-line. Please visit our [Online Ordering Zone](#) for a convenient and prompt service.

Upcoming events

Screening Europe 2004 April, 21-22 2004
London, UK

[More about events](#)

Online Ordering

INTELLIGENT CHOICE INTELLIGENT
LEADS

ASINEX is proud to present Online Ordering possibility which is designed to offer you many of the most popular compounds at the touch of a finger. All of these compounds are of the highest quality with a purity level of at least 90% (average 95%), 100% NMR identification, and LC - MS for 25% of the compounds. We guarantee confirmation of your order within one business day and provide fast and reliable delivery.

[Enter Online Ordering Zone](#)

[Home](#) | [Map](#) | [Contacts](#) | [News](#) | [About ASINEX](#) | [Products](#) | [E-shop](#) | [Services](#) | [Online Feedback](#) | [FAQ](#)
© 2003 ASINEX Ltd. All rights reserved

Phone +7 095 780 3411 +7 095 728 3891 Fax +7 095 780 3419 asinex@asinex.com